

SYNTHESIS, CRYSTAL STRUCTURE AND ANTITUMOR ACTIVITY OF A Zn(II) COMPLEX WITH 1,2-PHENYLENEDIOXYDIACETIC ACID

Xi-Shi Tai^{1*}, Jie Yin², Yuan-Yuan Liu¹

¹Weifang University, College of Chemistry and Chemical Engineering,
Weifang 261061, P. R. China

²College of Applied Chemistry and Environmental Engineering, Xinyang
Vocational and Technical College, Xinyang 464000, P. R. China

*Corresponding author: taixishi@lzu.edu.cn

Received: November, 21, 2014

Accepted: December, 12, 2014

Abstract: A novel Zn(II) complex, $[\text{Zn}(\text{L})(\text{H}_2\text{O})_3] \cdot 2\text{H}_2\text{O}$, has been obtained by reaction of $\text{Zn}(\text{OAc})_2 \cdot 2\text{H}_2\text{O}$ with 1,2-phenylenedioxydiacetic acid in $\text{CH}_3\text{OH}/\text{H}_2\text{O}$. It was characterized by elemental analysis, IR and X-ray single crystal diffraction analysis. The crystal of the title complex belongs to monoclinic, space group $C2/c$ with $a = 29.283(7) \text{ \AA}$, $b = 6.7305(15) \text{ \AA}$, $c = 17.243(3) \text{ \AA}$, $\beta = 109.25(3)^\circ$, $V = 3208.4(12) \text{ \AA}^3$, $Z = 8$, $D_c = 1.621 \text{ mg} \cdot \text{m}^{-3}$, $\mu = 1.590 \text{ mm}^{-1}$, $F(000) = 1576$, and final $R_1 = 0.1284$, $\omega R_2 = 0.3895$. X-ray analysis reveals that the Zn(II) center is seven-coordination with a O_7 distorted pentagonal bipyramidal coordination environment. The Zn(II) complex molecules form 1D chain structure by the hydrogen bonds and π - π stacking interactions. The antitumor activity of 1,2-phenylenedioxydiacetic acid ligand and its Zn(II) complex against human intestinal adenocarcinoma *HCT-8* cells, lung adenocarcinoma *HCT-116* cells and human lung adenocarcinoma *A549* cells line have been investigated.

Keywords: antitumor activity, crystal structure,
1,2-phenylenedioxydiacetic acid, synthesis, Zn(II) complex

INTRODUCTION

Metal complexes of multidentate ligands have received considerable attention over the past two decades [1 - 5]. This may be attributed to unusual structural features in the resultant metal complexes and their biological activities. Some of the metal complexes have antitumor properties [6], antioxidative activities [7], electronic and photophysical properties [8]. As part of our group to explore the synthesis and property of metals complex, we have been exploring the preparation of metal-organic hybrid materials by combining metal ions and organic ligands [9 - 12]. In this paper, A novel Zn(II) complex has been obtained and characterized by elemental analysis, IR, UV spectra, molar conductivity and X-ray single crystal diffraction analysis. The antitumor activity of 1,2-phenylenedioxydiacetic acid ligand and its Zn(II) complex against human intestinal adenocarcinoma *HCT-8* cells, lung adenocarcinoma *HCT-116* cells and human lung adenocarcinoma *A549* cells line have been investigated.

EXPERIMENTAL

Materials and methods

The following A. R. grade chemicals and other solvents were used for the preparation of the studied compound without further purifications: Zn(OAc)₂·2H₂O, 1,2-phenylenedioxydiacetic acid, sodium hydroxide.

Elemental analysis (C, H, N) was carried out on a Elementar Vario III EL elemental analyzer. The FT-IR spectra were obtained on a Nicolet AVATAR 360 FTIR spectrometer with KBr pellets in the range of 4,000 cm⁻¹-400 cm⁻¹. The crystal data was collected on a Bruker smart CCD Area Detector.

Synthesis of the Zn(II) complex

A solution of 1,2-phenylenedioxydiacetic acid (1.0 mmol, 0.226 g) and sodium hydroxide (2.0 mmol 0.080 g) in 10 mL CH₃OH/H₂O (v:v = 1:1) was stirred at room temperature. Then 0.5 mmol (0.109 g) of Zn(OAc)₂·2H₂O was added to the above solution. The mixture was continuously stirred for 3 h at refluxing temperature. The mixture was cooled at room temperature, and the resulting solution was filtered. The colourless crystals were obtained after the filtrate was kept in air for several days (52% yield). The results of the elemental analysis and IR data of Zn(II) complex are listed in Table 1.

Table 1. Results of the elemental analysis and IR data

Chemical formula	Elemental analysis (%)				IR ν_{\max} (cm ⁻¹)	
	C		H		$\nu(\text{O-H})$	$\nu(\text{COO}^-)$
	calc.	found	calc.	found		
C ₁₀ H ₁₈ ZnO ₁₁	31.61	31.38	4.74	4.43	3438	1629

X-ray Crystallography

A colourless block single crystal with dimensions of $0.22 \times 0.20 \times 0.16$ mm was selected for measurement. Diffraction data of the single crystal were collected by $\varphi\sim\omega$ scan mode using a graphite-monochromatic Mo $K\alpha$ radiation ($\lambda = 0.71073$ Å) at 293(2) K on a Bruker Smart Apex CCD diffractometer. A total of 14480 reflections were collected in the range 3.12 – 27.48° , of which 3631 were unique ($R_{\text{int}} = 0.0450$) and 3203 were observed with $I > 2\sigma(I)$. The data were corrected for Lp factors. The structure was solved by direct methods and refined by full-matrix least-squares techniques on F^2 . The structure was solved by direct methods [13] using SHELXL-97 and expanded using Fourier techniques. All of the non-hydrogen atoms and hydrogen atoms were refined anisotropically and isotropically, respectively. Molecular graphics were drawn with the program package SHELXTL-97 crystallographic software package [14]. The most relevant crystal data for Zn(II) complex are quoted in Table 2, and selected bond lengths and angles are listed in Table 3 and Table 4.

Table 2. Crystallographic data for the title compound

Formula	C ₁₀ H ₁₈ O ₁₁ Zn
Formula weight	379.62
Cell setting	Monoclinic
Space group	<i>C2/c</i>
<i>a</i> (Å)	29.283(7)
<i>b</i> (Å)	6.7305(15)
<i>c</i> (Å)	17.243(3)
β (°)	109.25(3)
Volume (Å ³)	3208.4(12)
<i>Z</i>	8
<i>D_c</i> (Mg m ⁻³)	1.621
μ (mm ⁻¹)	1.590
Crystal size (mm)	0.22×0.20×0.16
Radiation (Å)	0.71073
Theta min–max (°)	3.12–27.48
Tot., uniq. data, <i>R</i> (int)	14480, 3631, 0.0450
Observed data [$I > 2 \sigma(I)$]	3203
<i>F</i> (000)	1576
Goodness-of-fit on F^2	3.276
<i>R</i> ₁ [$I > 2 \sigma(I)$]	0.1284
ωR_2 [$I > 2 \sigma(I)$]	0.3895
<i>R</i> ₁ (all data)	0.1352
ωR_2 (all data)	0.3981
Min. and max. resd. dens. [e/Å ³]	5.319 -0.753

Table 3. Selected bond lengths (Å) for the title compound

Bond	Distance	Bond	Distance
Zn1-O8	2.031(6)	Zn1-O10	2.055(5)
Zn1-O7	2.065(6)	Zn1-O2	2.110(5)
Zn1-O4	2.163(5)	Zn1-O6	2.463(5)
Zn1-O1	2.480(6)	C10-O5	1.271(8)
C3-O8	1.261(8)	C2-O6	1.373(8)
C9-O6	1.405(8)	C4-O10	1.243(7)
C2-O8	1.242(9)	C1-O1	1.354(9)
C7-O1	1.417(9)		

Table 4. Selected angles (°) for the title compound

Angle	(°)	Angle	(°)
O8-Zn1-O10	166.1(2)	O8-Zn1-O7	92.0(2)
O7-Zn1-O10	100.9(2)	O8-Zn1-O2	95.6(2)
O2-Zn1-O10	91.3(2)	O7-Zn1-O2	82.2(2)
O8-Zn1-O4	90.4(2)	O4-Zn1-O10	86.39(19)
O7-Zn1-O4	81.7(2)	O2-Zn1-O4	163.0(2)
O8-Zn1-O6	85.5(2)	O6-Zn1-O10	80.75(18)
O7-Zn1-O6	149.3(2)	O2-Zn1-O6	128.52(19)
O4-Zn1-O6	67.67(18)	O8-Zn1-O1	84.5(2)
O10-Zn1-O1	87.0(2)	O7-Zn1-O1	149.3(2)
O2-Zn1-O1	67.9(2)	O4-Zn1-O1	128.65(19)
O6-Zn1-O1	61.00(18)		

Antitumor activity

Human intestinal adenocarcinoma *HCT-8* cells, human lung adenocarcinoma *HCT-116* cells and human lung adenocarcinoma *A549* cells were propagated continuously in culture and grown in RPMI 1640 medium with 10 % inactivated fetal calf serum and antibiotics. Cell harvested from exponential phase were seeded equivalently into 96 well plates and incubated for 24 h and then compounds studied were added in a concentration gradient. The final concentrations were maintained at $c/(\mu\text{g}\cdot\text{mL}^{-1})$ 5, 10, 20, 30, 40, 60 respectively. The plates were maintained at 37°C in a humidified 5% CO₂ - 90% N₂ - 5% O₂ atmosphere and incubated for 48 h, the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) solution was added following the procedure referred to [15]. The measurements of absorption of the solution concerned with the number of live cells were performed on spectrophotometer at 570 nm.

RESULTS AND DISCUSSION

IR spectra

The IR spectrum of Zn(II) complex is shown in Figure 1. The $\nu_{as}(\text{COOH})$ and $\nu_s(\text{COOH})$ vibrations of free ligand are at 1666 and 1457 cm^{-1} . In the Zn(II) complex, they appear at 1629 and 1435 cm^{-1} . Which can be explained that the oxygen atoms of COO^- group take part in coordination with Zn(II) ions and the $\Delta\nu(\nu_{as}(\text{COOH}) - \nu_s(\text{COOH}))$ is 194 cm^{-1} , indicating that the carboxylates are unidentate coordinated with Zn(II) atoms. The broad peak at 3438 cm^{-1} is ascribed to the O-H stretching vibrations of the coordinated and uncoordinated water. The result of IR is in accordance with the results of X-ray single crystal diffraction analysis.




Figure 1. The IR spectrum of Zn(II) complex

Structure Description

The crystal structure of the Zn(II) complex is revealed in Figure 2. The molecular packing arrangement is shown in Figure 3.




Figure 2. Molecular structure of the Zn(II) complex, where the thermal ellipsoids were drawn at 30% possibility

As shown in Figure 2, in the crystal structure, the Zn(II) ion is seven-coordination by four oxygen atoms (O1, O2, O4, O6) from 1,2-phenylenedioxydiacetic acid ligand, three oxygen atoms (O7, O8, O10) from the coordinated water molecule, forming up a distorted pentagonal bipyramidal coordination environment. The distances of the Zn-O bonds are in the range of 2.031(6)-2.480(6) Å, and the distances of Zn-O are comparable with that observed in other Zn complexes [16, 17].




Figure 3. Molecular packing of the Zn(II) complex

The complex forms one dimensional chain structure along by the hydrogen bonds and π - π stacking interactions (Figure 4).




Figure 4. One dimensional chain structure of the Zn(II) complex

Antitumor activity

The data of antitumor activities of Zn(II) complex and 1,2-phenylenedioxydiacetic acid are given in Table 5. The concentration of DMSO was controlled under 1 % to assure not to affect the results. It can be seen that both Zn(II) complex and 1,2-phenylenedioxydiacetic acid exhibit cytotoxic effect against human intestinal adenocarcinoma *HCT-8* cells and human lung adenocarcinoma *HCT-116* cells. However, the antitumor effect of 1,2-phenylenedioxydiacetic acid is better than that of Zn(II) complex. 1,2-Phenylenedioxydiacetic acid has stronger cytotoxicity against human lung adenocarcinoma *A549* cells with lower IC_{50} ($7 \pm 2.3 \mu\text{g} \cdot \text{mL}^{-1}$), however, Zn(II) complex does not have effect.

Table 5. Antitumor activities of Zn(II) complex and 1,2-phenylenedioxydiacetic acid ligand

Compound	$IC_{50} \mu\text{g} \cdot \text{mL}^{-1}$		
	<i>HCT-8</i>	<i>HCT-116</i>	<i>A549</i>
1,2-phenylenedioxydiacetic acid	11 ± 1.3	14 ± 1.6	7 ± 2.3
Zn(II) complex	22 ± 1.9	17 ± 1.1	----

---- no antitumor activity

CONCLUSIONS

In summary, a novel Zn(II) complex has been obtained and characterized. The results show that Zn(II) center is seven-coordination with a O_7 distorted pentagonal bipyramidal coordination environment. The Zn(II) complex molecules form 1D chain structure by the interaction of hydrogen bonds and π - π stacking. The antitumor activity of 1,2-phenylenedioxydiacetic acid ligand and its Zn(II) coordination polymer against

human intestinal adenocarcinoma *HCT-8* cells, lung adenocarcinoma *HCT-116* cells and human lung adenocarcinoma *A549* cells line have been investigated.

ACKNOWLEDGMENTS

The authors would like to thank the National Natural Science Foundation of China (No. 21171132), the Project of Shandong Province Higher Educational Science and Technology Program (J14LC01) and Science Foundation of Weifang.

REFERENCES

1. Tao, R.J., Li, F.A., Zang, S.Q., Cheng, Y.X., Niu, J.Y.: Synthesis, characterization, properties and crystal structure of $\{[\text{CuLZn} \cdot \text{CuLZn} \cdot (\text{H}_2\text{O})] \cdot (\text{H}_2\text{O})\}_n$, *Science in China, Series B*, **2006**, 36, 47-52;
2. Tian, L.J., Yang, H.J., Zheng, X.L., Ni, Z.H., Yan, D.M., Tu, L.L., Jiang, J.Z.: Synthesis, structural characterization and cytotoxic activity of diorganotin(IV) complexes of N-(5-halosalicylidene)tryptophane, *Applied Organometallic Chemistry*, **2009**, 23, 24-31;
3. Huang, X.G., Wang, Q., Yan, X.H., Xu, J., Liu, W.S., Wang, Q., Tang, Y.: Encapsulating a ternary europium complex in a silica/polymer hybrid matrix for high performance luminescence application, *Journal of Physical Chemistry C*, **2011**, 115, 2332-2340;
4. Tai, X.S., Zhao, W.H.: Synthesis, spectral characterization, and luminescence properties of a cup-like ligand and its magnesium (II) complex, *Research on Chemical Intermediates*, **2014**, 40, 2075-2082;
5. Tai, X.S., Feng, Y.M., Sun, X.Z., Tan, M.Y.: Synthesis, spectral characterization and luminescent properties of ternary rare earth nitrates complexes with 1,1,1-tris-[1'-(2'-oxa-4'-oxo-5'-aza-5'-bisphenyl)hexyl]propane and pyridine-N-oxide ligand, *Polish Journal of Chemistry*, **2008**, 82, 993-999;
6. Yu, S.Y., Wang, Q.M., Wu, B., Wu, X.T., Hu, H.M., Wang, L.F., Wu, A.X.: Synthesis and crystal structure of the cryptate complex $[\text{Gd}(\text{L})(\text{DMF})] \cdot \text{KSCN} \cdot \text{CH}_3\text{CN} \cdot 3\text{H}_2\text{O}$ (L is a deprotonated phenol-based N8O3 cryptand), *Polyhedron*, **1997**, 16, 321-325;
7. Thibon, A., Karmazin-Brelot, L., Mandon, D.: Coordination versatility and amide shift in mononuclear Fe^{II} complexes with the asymmetrical tripod [(6-bromo-2-pyridyl)methyl][(6-pivaloylamido-2-pyridyl)methyl](2-pyridylmethyl) amine (BrMPPA), *European Journal of Inorganic Chemistry*, **2013**, 2013 (7), 1118-1122;
8. Zeng, L.L., Xiao, Y., Liu, J., Tan, L.F.: Synthesis, characterization, DNA-binding and cytotoxic properties of Ru(II) complexes: $[\text{Ru}(\text{MeIm})_4\text{L}]^{2+}$ (MeIm = 1-methylimidazole, L = phen, ip and pip), *Journal of Molecular Structure*, **2012**, 1019, 183-190;
9. Tai, X.S., Wei, N., Wang, D.H.: Synthesis, crystal structure and luminescent property of Mg (II) complex with *N*-benzenesulphonyl-L-leucine and 1,10-phenanthroline, *Materials*, **2012**, 5, 558-565;
10. Tai, X.S., Li, Y.F., Zhao, W.H.: Synthesis and crystal structure of Mg (II) complex with 3-amino-2-pyrazinecarboxylic acid ligand, *Journal of Chemical and Pharmaceutical Research*, **2014**, 6, 516-520;
11. Tai, X.S., Zhao, W.H.: Synthesis, crystal structure and antitumor activity of Ca(II) coordination polymer based on 1,5-naphthalenedisulfonate, *Journal of Inorganic and Organometallic Polymers and Materials*, **2013**, 23, 1354-1357;
12. Tai, X.S., Zhao, W.H.: Synthesis, structural characterization, and antitumor activity of a Ca(II) coordination polymer based on 1,6-naphthalenedisulfonate and 4,4'-bipyridyl, *Materials*, **2013**, 6, 3547-3555;
13. Sheldrick, G.M.: *SHELXL-97, Program for Crystal Structure Solution*; University of Göttingen: Göttingen, Germany, **1997**;

14. Sheldrick, G.M.: *SHELXTL-97, Program for Crystal Structure Refinement*; University of Göttingen: Göttingen, Germany, **1997**;
15. Dodoff, N., Grancharov, K., Gugova, R., Spassovska, N.: Platinum (II) complexes of benzoic- and 3-methoxybenzoic acid hydrazides. Synthesis, characterization, and cytotoxic effect, *Journal of Inorganic Biochemistry*, **1994**, **54**, 221-233;
16. Tai, X.S., Feng, Y.M., Kong, F.Y., Wang, D.Q., Tan, M.Y.: Synthesis, crystal structure and fluorescence property of 3-ethoxysalicylaldehyde-N,N-bis(3-aminopropyl)-methylamine Zn(II) complex, *Chinese Journal of Inorganic Chemistry*, **2008**, **24**, 319-323;
17. Wang, D. Z., Sun, X.S., Zhang, J.B., Liu, C.J., Bai, M.: Transitional metal complexes with 1,2,4-triazole ligand: synthesis and crystal structures, *Chinese Journal of Structural Chemistry*, **2013**, **32**, 1733-1741.